Published in Hepatitis Weekly, June 9th, 1997
University of Washington researcher Stephen J. Polyak and colleagues found that quasispecies diversity appears to be an independent variable of hepatitis C virus (HCV) quasispecies heterogeneity, and that gel shift technology is an accurate measure of this diversity.
Interferon treatment for patients with HCV disease leads to a positive biochemical response in 40 to 50 percent of cases, and to a sustained response (sustained clearance of HCV RNA) in approximately 15 percent of patients.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.